GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocera Therapeutics Inc (NAS:OCRX) » Definitions » Owner Earnings per Share (TTM)

Ocera Therapeutics (Ocera Therapeutics) Owner Earnings per Share (TTM) : 0.00 (As of Sep. 2017)


View and export this data going back to 2011. Start your Free Trial

What is Ocera Therapeutics Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Ocera Therapeutics's Owner Earnings per Share (TTM) ended in Sep. 2017 was $0.00. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Ocera Therapeutics's Owner Earnings per Share (TTM) or its related term are showing as below:



OCRX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.175
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Ocera Therapeutics's Earnings per Share (Diluted) for the three months ended in Sep. 2017 was $-0.24. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2017 was $-0.96. It's PE Ratio ratio for today is At Loss.

Ocera Therapeutics's EPS without NRI for the three months ended in Sep. 2017 was $-0.24. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2017 was $-0.96. It's PE Ratio without NRI ratio for today is At Loss.


Ocera Therapeutics Owner Earnings per Share (TTM) Historical Data

The historical data trend for Ocera Therapeutics's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocera Therapeutics Owner Earnings per Share (TTM) Chart

Ocera Therapeutics Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only - - -1.22 -1.22 -1.14

Ocera Therapeutics Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.22 -1.14 -1.14 -0.99 -0.96

Competitive Comparison of Ocera Therapeutics's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, Ocera Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocera Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocera Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Ocera Therapeutics's Price-to-Owner-Earnings falls into.



Ocera Therapeutics Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Ocera Therapeutics's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -24.24
Depreciation, Depletion and Amortization 0.04
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 0.03
Change In Working Capital -1.18
Shares Outstanding (Diluted Average) 26.51

1. Start with "Net Income" from income statement. Ocera Therapeutics's Net Income for the trailing twelve months (TTM) ended in Sep. 2017 was $-24.24 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Ocera Therapeutics's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Sep. 2017 was $0.04 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Ocera Therapeutics's Change In Deferred Tax for the trailing twelve months (TTM) ended in Sep. 2017 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $0.03 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Ocera Therapeutics's 5-Year Average Maintenance Capital Expenditure = $0.03 Mil

5. "Change In Working Capital" is from cashflow statement. Ocera Therapeutics's Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2017 was $-1.18 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Ocera Therapeutics's Shares Outstanding (Diluted Average) for the months ended in Sep. 2017 was 26.511 Mil.

Ocera Therapeutics's Onwer Earnings Per Share for Sep. 2017 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -24.238 +0.039+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.033333333333333+-1.178)/26.511
=0.00

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=1.79/0.00
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Ocera Therapeutics Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Ocera Therapeutics's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocera Therapeutics (Ocera Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
525 University Avenue, Suite 610, Palo Alto, CA, USA, 94301
Ocera Therapeutics Inc is a clinical-stage biopharmaceutical company, which primarily targets acute and chronic orphan liver diseases. The company is focused on the development and commercialization of a clinical product candidate, OCR-002 for the treatment of acute and chronic hepatic encephalopathy for patients with a serious complication of liver cirrhosis, or liver failure, marked by mental changes including confusion, impaired motor skills, disorientation in time and space, and, in its more severe form, stupor, coma and even death. All the business activity of the firm is functioned through the region of US.
Executives
Brian H Dovey 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Steven P James director C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Wendall Wierenga director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Nina S Kjellson director C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Domain Partners Viii, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Dp Viii Associates, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber director C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Kim P. Kamdar 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Brian K Halak 10 percent owner C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Dp Vi Associates, L.p. 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Associates Domain 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Domain Partners Vi, L.p. 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Nicole Vitullo 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
James C Blair 10 percent owner 5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Jesse I Treu 10 percent owner

Ocera Therapeutics (Ocera Therapeutics) Headlines

From GuruFocus

Three Insider Buys at 52-Week Lows

By Monica Wolfe Monica Wolfe 07-22-2014

Top 3 Insider Buys of the Week

By Monica Wolfe Monica Wolfe 07-19-2013